Drugs Containing Excipient (Inactive Ingredient) PENTAERYTHRITOL

Generic drugs containing PENTAERYTHRITOL excipient

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	halobetasol propionate	0713-0339	PENTAERYTHRITOL
Cosette Pharmaceuticals Inc	halobetasol propionate	0713-0639	PENTAERYTHRITOL
QUAGEN PHARMACEUTICALS LLC	halobetasol propionate	70752-119	PENTAERYTHRITOL
Bryant Ranch Prepack	halobetasol propionate	72162-2067	PENTAERYTHRITOL
Bryant Ranch Prepack	halobetasol propionate	72162-2258	PENTAERYTHRITOL

Pentaerythritol Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 8, 2026

Pentaerythritol is a small-volume, commodity-derived polyol with limited documented use as a pharmaceutical excipient. Its commercial economics are driven primarily by alkyd resins, coatings, adhesives, flame retardants, plasticizers and specialty polymers, not pharmaceutical formulations. No reliable public source reports a standalone pharmaceutical pentaerythritol market, supplier revenue segment or dedicated patent estate.

The pharmaceutical opportunity is therefore a qualification and specialty-grade business rather than a high-growth drug-excipient franchise. Pricing power depends on purity, particle engineering, documentation, regulatory support and supply continuity. Volume growth is likely to remain modest unless a new formulation platform adopts pentaerythritol at meaningful scale.

What is pentaerythritol and how is it used in pharmaceuticals?

Pentaerythritol is a tetrafunctional polyol with the molecular formula C5H12O4 and CAS Registry Number 115-77-5. It is manufactured by reacting acetaldehyde with formaldehyde under alkaline conditions, followed by purification and crystallization.

Attribute	Data
Chemical name	2,2-bis(hydroxymethyl)-1,3-propanediol
Common abbreviation	PET
CAS number	115-77-5
Molecular weight	136.15 g/mol
Physical form	White crystalline powder
Primary industrial role	Alkyd-resin and coating intermediate
Pharmaceutical role	Limited, formulation-specific excipient or processing ingredient
Regulatory category	Not an active pharmaceutical ingredient
Biosimilar relevance	None
Orange Book relevance	Generally none as a standalone active drug substance

Pentaerythritol has four hydroxyl groups, which gives it high functionality and strong reactivity in polymer systems. In pharmaceutical development, those same properties can support specialized applications involving binding, matrix formation, controlled release, solid dispersions or chemical derivatization. Its high melting point and crystalline nature can also be useful in dosage-form design, although they can create processing challenges.

The available public record does not establish broad, standardized use comparable with microcrystalline cellulose, lactose, mannitol, povidone or polyethylene glycol. Pentaerythritol should therefore be analyzed as a niche excipient with a larger industrial parent market.

How large is the pharmaceutical pentaerythritol market?

No authoritative public dataset isolates pharmaceutical-grade pentaerythritol sales from total pentaerythritol revenue. Commercial market studies typically aggregate pentaerythritol across coatings, plastics, lubricants, flame retardants and other industrial applications. Pharmaceutical demand is likely a small fraction of total consumption.

The market structure has four layers:

1. Bulk pentaerythritol production.
2. Higher-purity or tightly specified grades.
3. Pharmaceutical qualification, documentation and regulatory support.
4. Contract supply and formulation-specific customization.

The first layer is capacity-driven and exposed to feedstock costs. The third and fourth layers can earn higher margins but require lower-volume technical service, validation and quality-control capabilities.

What drives demand for pentaerythritol?

The main demand drivers are:

• Growth in alkyd coatings and synthetic resins.
• Expansion of flame-retardant and intumescent materials.
• Specialty polymer development.
• Demand for high-purity excipients and functional solid-form ingredients.
• Formulation work involving controlled release or polymeric matrices.
• Regional sourcing and supply-chain diversification.

Pharmaceutical demand is less correlated with prescription-drug volume than common excipients because pentaerythritol is not a routine filler or diluent. Adoption depends on whether a formulation delivers a measurable technical advantage over established excipients.

What is the financial trajectory for pentaerythritol suppliers?

The likely financial trajectory is stable-to-cyclical rather than pharmaceutical-growth driven. Bulk producers are exposed to industrial production, construction activity, coatings demand and raw-material pricing. Specialty-grade suppliers can achieve better gross margins, but the addressable volume is narrower.

Revenue and margin drivers

Driver	Financial effect
Formaldehyde and acetaldehyde costs	Direct impact on production margin
Plant utilization	Strong effect on unit economics
Coatings and resin demand	Main volume driver
Energy and logistics costs	Margin volatility
Product purity and particle control	Supports premium pricing
Pharmaceutical qualification	Raises switching costs
Single-source status	Can improve account retention
Regulatory documentation	Adds cost but supports customer approval
Capacity expansions	Can pressure prices if demand lags

Perstorp identifies pentaerythritol among its specialty chemical products and markets grades under the PETOL product family. Ercros also produces pentaerythritol as part of its formaldehyde-derivatives portfolio. These businesses are positioned primarily around industrial chemistry rather than pharmaceutical excipient revenue [1][2].

The financial profile is therefore likely to show:

• Volume growth tied to industrial end markets.
• Periodic price increases during supply tightness.
• Margin compression when new capacity or weak coatings demand affects utilization.
• Higher retention in qualified pharmaceutical accounts.
• Limited earnings contribution from pharmaceutical sales unless a supplier develops a differentiated excipient grade.

Public company disclosures generally do not separate pharmaceutical-grade pentaerythritol revenue. Any precise estimate of pharmaceutical sales, market share or EBITDA contribution would be speculative.

Which companies supply pentaerythritol?

The competitive field includes large specialty-chemical producers, regional chemical manufacturers and Chinese producers. The market is more fragmented than the market for major pharmaceutical excipients because industrial grades are widely available.

Company or group	Position in value chain	Pharmaceutical relevance
Perstorp	Specialty chemical producer; PETOL grades	Strong technical and documentation potential
Ercros	European chemical producer	Industrial supply and regional coverage
Chinese producers	Large regional and export capacity	Cost competition; qualification varies
Indian and other Asian producers	Regional chemical supply	Potential alternative sourcing
Distributors	Local inventory and customer support	Useful for low-volume demand

Supplier selection for pharmaceutical use depends on more than assay. Buyers typically assess:

• GMP or excipient-quality systems.
• Elemental impurities.
• Residual solvents and aldehydes.
• Microbial controls.
• Particle-size distribution.
• Polymorphic or solid-state consistency.
• Change-control procedures.
• Audit access.
• Stability and packaging.
• Supply-continuity planning.

A bulk industrial supplier may meet chemical specifications but still require substantial qualification before use in a regulated drug product.

What is the FDA regulatory status of pentaerythritol?

Pentaerythritol is not an approved active pharmaceutical ingredient. Its regulatory position depends on its role in a specific formulation and the applicable route of administration.

The FDA Inactive Ingredient Database is the principal public reference for inactive ingredients used in approved drug products. Inclusion in the database, where applicable, does not constitute broad approval for every formulation, strength or route. Sponsors remain responsible for demonstrating identity, quality, safety and suitability in the finished product [3].

The relevant regulatory pathways are:

Oral solid dosage forms

An oral tablet or capsule using pentaerythritol would normally be reviewed through an NDA or ANDA, depending on the product. The sponsor would need to establish the excipient's identity, specifications, manufacturing controls and compatibility with the active ingredient.

Novel or high-level use

A new route, unusually high exposure or materially different function could trigger additional toxicological and regulatory scrutiny. The safety assessment would depend on dose, administration route, exposure duration and formulation context.

European Union status

European use would require assessment against applicable excipient quality, safety and manufacturing expectations. A European Pharmacopoeia monograph should not be assumed without verification for the specific grade. Industrial compliance under REACH does not by itself establish suitability as a pharmaceutical excipient [4].

What patents protect pharmaceutical pentaerythritol formulations?

There is no widely recognized, standalone patent estate protecting pentaerythritol as a pharmaceutical excipient. Basic composition-of-matter protection for pentaerythritol is long expired because the compound has been known for more than a century.

Potentially relevant patent categories include:

• Pharmaceutical compositions containing pentaerythritol.
• Controlled-release matrices.
• Crosslinked or derivatized pentaerythritol polymers.
• Solid dispersions.
• Drug-delivery systems using multifunctional polyols.
• Manufacturing processes that control crystal size or purity.
• Specific combinations with active pharmaceutical ingredients.

These rights would generally protect a formulation or manufacturing process, not the underlying excipient itself. Patent risk must therefore be assessed at the product level.

How strong is the patent estate?

The base-material patent estate is weak or effectively expired. The formulation-level estate can still be relevant when pentaerythritol is an essential component of a protected dosage form.

Patent layer	Expected status
Basic pentaerythritol compound	Expired
Bulk synthesis	Mostly mature and crowded
Pharmaceutical grade specification	Potentially protectable through process or quality claims
Drug formulation	Potentially active, product-specific
Controlled release	Potentially active, technology-specific
Manufacturing process	Depends on process novelty
Supplier-specific grade	Usually protected through know-how and quality systems

No major public record establishes a pentaerythritol-centered Orange Book patent strategy. Any patent search should focus on the specific drug product, formulation architecture and jurisdiction.

When does pentaerythritol lose exclusivity?

Pentaerythritol itself has no meaningful remaining composition-of-matter exclusivity. It is a mature chemical available from multiple producers.

Pharmaceutical exclusivity can still arise from:

• A patent covering a specific formulation.
• A method-of-use patent.
• A process patent.
• Regulatory exclusivity attached to a finished drug.
• Trade secrets involving particle engineering or purification.

The timing of generic entry would depend on the protected drug product rather than on pentaerythritol. A generic manufacturer could generally source pentaerythritol from a qualified supplier unless a formulation patent or regulatory requirement imposed a barrier.

Are there Paragraph IV challenges or patent litigation?

No major, widely reported Paragraph IV campaign is centered on pentaerythritol as an excipient. Paragraph IV litigation applies to an ANDA applicant challenging patents listed for an approved drug in the FDA Orange Book. An excipient normally does not have an Orange Book listing as an active ingredient.

Patent disputes could arise indirectly when:

• A generic product uses pentaerythritol in a patented dosage form.
• A branded drug lists a method-of-use patent covering the formulation.
• A supplier alleges infringement of a process or particle-engineering patent.
• A drug sponsor challenges equivalence or formulation substitution.

There is no established pentaerythritol-specific settlement pattern comparable with major small-molecule drugs.

What manufacturing and intellectual-property barriers affect supply?

The principal barriers are operational, not patent-based.

Manufacturers must control:

• Reaction conversion and impurity formation.
• Residual formaldehyde and acetaldehyde.
• Crystal morphology.
• Moisture and caking.
• Particle-size distribution.
• Packaging integrity.
• Batch-to-batch consistency.
• Change notification.

Pharmaceutical customers may qualify a supplier over several development and commercial batches. Once approved, replacement can require comparability work, stability testing and regulatory notification. This creates practical switching costs even when the chemical itself is not proprietary.

Manufacturing concentration is a greater commercial risk than patent expiry. A plant outage, export restriction, energy shock or feedstock disruption can affect supply across industrial and pharmaceutical customers.

How does pentaerythritol compare with common pharmaceutical excipients?

Excipient	Pharmaceutical adoption	Typical role	Competitive position versus pentaerythritol
Microcrystalline cellulose	Very high	Binder, filler, disintegrant	Lower regulatory and supply risk
Mannitol	High	Diluent, chewable and lyophilized products	Broader established use
Povidone	High	Binder, solubilizer	Stronger formulation ecosystem
Polyethylene glycol	High	Solvent, plasticizer, carrier	More versatile across dosage forms
Pentaerythritol	Limited and specialized	Formulation-specific functional excipient	Potential technical differentiation, limited market depth

Pentaerythritol can compete when a formulation needs a specific thermal, crystalline or multifunctional property. It is less competitive when the objective is low cost, broad compendial precedent or simple tablet manufacture.

What licensing deals and commercial partnerships exist?

There is no well-documented licensing market for pentaerythritol as a standalone pharmaceutical excipient. Commercial arrangements are more likely to involve:

• Supply agreements.
• Distributor appointments.
• Custom-grade development.
• Technical qualification agreements.
• Joint development of drug-delivery systems.
• Confidential formulation licenses.

A supplier with pharmaceutical-grade documentation could capture value through preferred-vendor status rather than through royalty-bearing composition licenses.

What generic launch risks exist?

Generic entry risk is low for pentaerythritol as a chemical and potentially high for a drug product using it in a protected formulation.

Low-risk scenario

A sponsor uses pentaerythritol as a nonfunctional filler or processing aid, with no patent claims directed to the ingredient. Alternative suppliers can be qualified, and generic manufacturers can source the material.

Medium-risk scenario

The product depends on a narrow particle-size distribution, crystal form or manufacturing sequence. Substitution is technically possible but requires formulation development and equivalence work.

High-risk scenario

Pentaerythritol is essential to a controlled-release, matrix, prodrug or delivery platform covered by active patents. Generic entry may require a non-infringing formulation or litigation.

What is the outlook for pentaerythritol through 2030?

The base case is modest growth in total pentaerythritol demand, led by industrial coatings, resins and specialty materials. Pharmaceutical-grade demand should grow from a small base if suppliers improve regulatory documentation and formulators identify applications where conventional excipients underperform.

The most attractive commercial opportunities are:

• High-purity grades.
• Low-metal and low-aldehyde specifications.
• Controlled particle-size products.
• Direct technical support for drug-product developers.
• Dual sourcing for regulated customers.
• Formulation-specific grades supported by compatibility data.

The main downside risks are weak industrial demand, excess Asian capacity, limited pharmaceutical adoption and substitution by established excipients.

Key Takeaways

• Pentaerythritol is a mature polyol, not a protected pharmaceutical active ingredient.
• Its primary market is industrial, especially coatings and alkyd resins.
• Pharmaceutical use is niche and formulation-specific.
• No reliable public source isolates pharmaceutical pentaerythritol revenue.
• The base-material patent estate is effectively expired.
• Formulation, process and particle-engineering patents may still create product-specific barriers.
• Pentaerythritol has no meaningful standalone Orange Book or biosimilar exposure.
• Financial performance depends mainly on industrial volume, feedstocks, capacity utilization and specialty-grade premiums.
• The strongest pharmaceutical opportunity is in qualified, documented, high-purity grades rather than bulk volume.
• Generic risk is low for the excipient itself but can be significant for a protected drug formulation.

FAQs About Pentaerythritol as a Pharmaceutical Excipient

Is pentaerythritol listed as an FDA-approved excipient?

Pentaerythritol is not approved as an active drug. Its acceptability as an inactive ingredient depends on the FDA Inactive Ingredient Database, the proposed route and dose, and the sponsor's product-specific justification.

Is pentaerythritol used in tablets?

It can be used in specialized formulation work, but it is not a mainstream tablet diluent or binder. Microcrystalline cellulose, lactose, mannitol and povidone have much broader commercial adoption.

Can pentaerythritol be replaced by another excipient?

Replacement is possible in many formulations, but not automatically. If pentaerythritol controls release, crystallinity, mechanical strength or another critical attribute, substitution may require reformulation and equivalence testing.

Does pentaerythritol have a pharmaceutical monograph?

A pharmaceutical monograph should not be assumed for every market or grade. Sponsors must verify applicable compendial coverage and establish appropriate specifications for the intended use.

Is pentaerythritol exposed to biosimilar competition?

No. Pentaerythritol is a synthetic small molecule and excipient, not a biologic medicine. Biosimilar regulations do not apply to it.

References

1. Perstorp Group. (n.d.). Pentaerythritol and PETOL product information. Perstorp Group.

2. Ercros, S.A. (2024). Annual report 2023. Ercros.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

4. European Chemicals Agency. (n.d.). Pentaerythritol substance information. ECHA.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. National Center for Biotechnology Information. (n.d.). Pentaerythritol compound summary. PubChem.